(1) Our inhaled liposomal iloprost (L608), with its innovative R&D strength and remarkable clinical performance, has been selected for an oral presentation at the 2025 Annual European Congress of Rheumatology (EULAR 2025).
(2) The presentation will be part of the session titled: “Clinical Abstract Session: Interstitial Lung Disease in Systemic Sclerosis (SSc-ILD) – Clinical Challenges and Evolving Therapeutic Strategies”, where the latest SSc clinical trials will be reported.
(3) The Phase I clinical trial of inhaled liposomal iloprost (L608) were also selected as one of the clinical trials in this year's Highlights from Clinical Science, and will be reported by EULAR on 14 June, 2025.
(4) EULAR is one of the most influential global academic congresses in the field of rheumatology, organized annually by the European Alliance of Associations for Rheumatology (EULAR). It attracts over 18,000 participants, including clinicians, researchers, industry professionals, and patient representatives from around the world. The congress focuses on the latest research, clinical challenges, therapeutic innovations, and collaborative efforts in rheumatology.
(5) Being selected for this presentation not only highlights the innovative potential of L608 in addressing unmet medical needs but also demonstrates our company's outstanding capabilities in global drug development and growing academic influence. We look forward to engaging with international experts, advancing clinical progress, and accelerating our commitment to delivering novel treatment options to patients.
(6)Presentation file : https://pse.im/7qafy3 |
